Literature DB >> 23596137

Prevalence and predictors of low bone mineral density in males with ulcerative colitis.

Nabeel Khan1, Ali M Abbas, Rawaa M Almukhtar, Amna Khan.   

Abstract

CONTEXT: Low bone mineral density (BMD) is common in patients with inflammatory bowel diseases.
OBJECTIVE: The objective of the study was to assess the prevalence and the predictors of low BMD (osteoporosis or osteopenia) and fragility fractures among men with ulcerative colitis.
DESIGN: This was a retrospective database analysis.
SETTING: The study was conducted at a nationwide Veterans Affairs health care system. PATIENTS: Male ulcerative colitis patients who were followed up in the Veterans Affairs system between 2001 and 2011 were identified using the International Classification of Diseases, ninth revision (ICD-9). MAIN OUTCOME MEASURES: We identified patients with low BMD and fragility fractures using ICD-9 codes. Steroid exposure was assessed using pharmacy data. A multivariate analysis was used to identify the independent effect of systemic steroids on the risk of low BMD and fragility fractures.
RESULTS: We identified 34 665 patients. Among them, 31% used steroids. The prevalence of low BMD was 15.8% and 7.1% among those who used and did not use steroids, respectively (P < .001). Prevalence of fragility fractures was 7.9%, 4.4%, and 1.1% for those with osteoporosis and osteopenia and those without low BMD, respectively (P < .001). Steroid exposure showed a dose-response pattern, patients who had cumulative prednisone exposure of greater than 11 136 mg (10th decile) were more likely to develop low BMD (odds ratio 8.9, P < .001) and fragility fractures (odds ratio 1.8, P < .001) as compared with non-steroid users after controlling for other possible predictors.
CONCLUSION: In this nationwide cohort, the prevalence of low BMD was higher than what was reported for the general male population. There was a strong correlation between the cumulative steroid use and the risk of low BMD. Both steroids and low BMD were independent risk factors for fragility fractures.

Entities:  

Mesh:

Year:  2013        PMID: 23596137     DOI: 10.1210/jc.2013-1332

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Management of Ulcerative Colitis in the Elderly.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

2.  Predictive Validity of the Beers and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States.

Authors:  Joshua D Brown; Lisa C Hutchison; Chenghui Li; Jacob T Painter; Bradley C Martin
Journal:  J Am Geriatr Soc       Date:  2016-01       Impact factor: 5.562

3.  Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.

Authors:  Jennifer C Lai; Dolores M Shoback; Jacob Zipperstein; Blanca Lizaola; Samuel Tseng; Norah A Terrault
Journal:  Dig Dis Sci       Date:  2015-01-07       Impact factor: 3.199

Review 4.  Managing osteoporosis in ulcerative colitis: something new?

Authors:  Luca Petruccio Piodi; Alessandro Poloni; Fabio Massimo Ulivieri
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

5.  Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification.

Authors:  Othman R Alharbi; Nahla A Azzam; Ahmed S Almalki; Majid A Almadi; Khalid A Alswat; Nazia Sadaf; Abdulrahman M Aljebreen
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

6.  Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis.

Authors:  Mirella Brasil Lopes; Andre Castro Lyra; Raquel Rocha; Fernanda Gomes Coqueiro; Carla Andrade Lima; Carolina Cunha de Oliveira; Genoile Oliveira Santana
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-07-05

Review 7.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

8.  Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis.

Authors:  Nabeel Khan; Ali Abbas; Alice Williamson; Luis Balart
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

Review 9.  Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications.

Authors:  Giovanni Maconi; Federica Furfaro; Roberta Sciurti; Cristina Bezzio; Sandro Ardizzone; Roberto de Franchis
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 10.  Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel.

Authors:  Fabio Massimo Ulivieri; Giuseppe Banfi; Valentina Camozzi; Annamaria Colao; Anna Maria Formenti; Stefano Frara; Giovanni Lombardi; Nicola Napoli; Andrea Giustina
Journal:  Endocrine       Date:  2021-05-17       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.